GYRE vs OKTA · rev $53.5M vs P/E 84, rev $1.57B
Gyre Therapeutics Inc. (GYRE) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Gyre Therapeutics Inc. (GYRE) is a biotechnology company listed on NASDAQ.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported GYRE revenue for 2026-06-30 was $53.5M. Net income was -$32.8M. GYRE currently screens at market cap $589.9M.
Latest reported OKTA revenue for 2026-07-31 was $1.57B. Net income was $190.0M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
GYRE currently screens at market cap $589.9M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the GYRE and OKTA stock pages for the full models.
Not investment advice.